Valuation: Aquestive Therapeutics, Inc.

Market Cap 49Cr 43Cr 40Cr 37Cr 70Cr 4.79TCr 71Cr 482.98Cr 188.39Cr 2.34TCr 185.59Cr 181.57Cr 8.1TCr P/E 2026 *
-9.73x
P/E 2027 * -10.1x
Enterprise Value 41Cr 36Cr 33Cr 31Cr 58Cr 3.96TCr 59Cr 399.94Cr 156Cr 1.93TCr 153.67Cr 150.35Cr 6.71TCr EV / Sales 2026 *
8.1x
EV / Sales 2027 * 6.87x
Free-Float
96.94%
Yield 2026 *
-
Yield 2027 * -
1 day-2.92%
1 week-3.05%
Current month-8.17%
1 month-24.06%
3 months-6.14%
6 months+17.90%
Current year-40.87%
1 week 3.81
Extreme 3.814
4.18
1 month 3.81
Extreme 3.814
5.18
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Sell

Chief Executive Officer

-20,369 0.0162%
23/06/26 Fiscal year

Director

75,000 0.0598%
15/06/26 Sell

Chief Executive Officer

-25,000 0.0199%
Change 5-day change 1-year change 3-year change Capi.($)
-2.66%-3.05%-10.33%+146.45% 49Cr
+1.54%+0.96%+47.75%+156.98% 1,03700Cr
+1.17%+3.34%+52.76%+51.00% 62TCr
+1.15%+0.64%+34.36%+78.81% 45TCr
+5.14%+5.40%+33.75%+27.79% 33TCr
+1.85%+3.57%+37.09%+40.59% 29TCr
-0.11%+0.48%+18.87%+17.70% 26TCr
+0.25%-4.62%-27.66%-41.76% 22TCr
+0.83%-0.89%+19.10%+56.44% 20TCr
+0.00%-4.54%+14.57%+67.54% 16TCr
Average +0.85%+0.98%+22.03%+60.15% 35.58TCr
Weighted average by Cap. +1.43%+1.47%+34.95%+75.38%

Financials

2026 *2027 *
Net sales 5.05Cr 4.44Cr 4.13Cr 3.8Cr 7.12Cr 489.17Cr 7.25Cr 49Cr 19Cr 238.59Cr 19Cr 19Cr 827.75Cr 7.19Cr 6.33Cr 5.88Cr 5.4Cr 10Cr 696.45Cr 10Cr 70Cr 27Cr 339.7Cr 27Cr 26Cr 1.18TCr
Net income -5.06Cr -4.45Cr -4.14Cr -3.81Cr -7.14Cr -490.48Cr -7.27Cr -49Cr -19Cr -239.23Cr -19Cr -19Cr -829.97Cr -4.8Cr -4.22Cr -3.92Cr -3.61Cr -6.76Cr -464.79Cr -6.88Cr -47Cr -18Cr -226.7Cr -18Cr -18Cr -786.5Cr
Net Debt -8.5Cr -7.48Cr -6.94Cr -6.39Cr -12Cr -823.16Cr -12Cr -83Cr -32Cr -401.5Cr -32Cr -31Cr -1.39TCr -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
24/26/24 $3.820 -3.05% 10,28,959
22/26/22 $3.940 -2.48% 17,07,558
21/26/21 $4.040 +2.41% 17,97,137
20/26/20 $3.945 -4.25% 14,34,370
17/26/17 $4.120 +4.57% 23,56,421
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.940USD
Average target price
8.889USD
Spread / Average Target
+125.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock